mAbs are already widely used in medicine and they have proven effectiveness in the treatment of cancer, HIV and other infectious diseases. MABLOC’s goals are to utilize mAbs to ameliorate suffering from infectious disease that they are already endemic in various parts of the world, and to anticipate new pandemics by using mAbs for prevention and treatment.

The company has access to laboratories, research centers and contacts in several points in the world and has a sophisticated laboratory with access to containment facilities in Washington, DC, United States.

MABLOC's team of experts is internationally recognized as authorities on the study and treatment of infectious diseases. Their complementary talents and knowledge and facilitate the development of mAbs from discovery to clinical use.

The combination of scientific knowledge, experience, and technology makes MABLOC an attractive investment opportunity, with enormous potential for growth.